{"id":744,"date":"2024-03-04T18:05:12","date_gmt":"2024-03-05T02:05:12","guid":{"rendered":"https:\/\/cloudbreakpharma.com\/?p=744"},"modified":"2024-03-21T21:39:22","modified_gmt":"2024-03-22T04:39:22","slug":"cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us","status":"publish","type":"post","link":"https:\/\/cloudbreakpharma.com\/zh_hk\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\/","title":{"rendered":"CBT-004\u5df2\u5728\u7f8e\u570b\u5b8c\u6210\u81e8\u5e8a2\u671f\u7684\u9996\u4f4d\u75c5\u4eba\u5165\u7d44"},"content":{"rendered":"<p>\u6211\u5011\u5f88\u81ea\u8c6a\u5730\u5ba3\u4f48\uff0cCBT-004 \u662f\u4e00\u7a2e\u6f5b\u5728\u7684\u8840\u7ba1\u5316\u7773\u5b54\u85e5\u7269\uff0c\u5df2\u65bc 2023 \u5e74 12 \u6708\u5728\u7f8e\u570b\u5b8c\u6210\u81e8\u5e8a2\u671f\u7684\u9996\u4f4d\u60a3\u8005\u5165\u7d44\u3002<\/p>\n<p>\u5145\u8840\u6027\u7d50\u819c\u9ec3\u6591\u662f\u4e00\u7a2e\u5713\u5f62\u3001\u6de1\u9ec3\u8272\u7684\u9686\u8d77\u7d44\u7e54\uff0c\u9577\u5728\u89d2\u819c\u9644\u8fd1\u7684\u7d50\u819c\u4e0a\uff0c\u7d2b\u5916\u7dda\u7684\u7d2f\u7a4d\u7167\u5c04\u662f\u9020\u6210\u5145\u8840\u6027\u7d50\u819c\u9ec3\u6591\u7684\u4e3b\u8981\u539f\u56e0\u3002 \u4e00\u822c\u800c\u8a00\uff0c\u7121\u75c7\u72c0\u7684\u77bc\u88c2\u6591\u7121\u9700\u6cbb\u7642\uff0c\u4f46\u5176\u6de1\u9ec3\u8272\u548c\u9686\u8d77\u7684\u8f2a\u5ed3\u53ef\u80fd\u6703\u5f15\u8d77\u6a5f\u68b0\u6027\u6216\u8207\u6dda\u819c\u4e0d\u826f\u6709\u95dc\u7684\u773c\u8868\u523a\u6fc0\u3002 \u7576\u75c5\u8b8a\u90e8\u4f4d\u8840\u7ba1\u5316\u53ca\u2571\u6216\u767c\u708e\u6642\uff0c\u53ef\u80fd\u6703\u5c0e\u81f4\u773c\u775b\u5145\u8840\u3001\u4e0d\u9069\u3001\u75bc\u75db\u3001\u7570\u7269\u611f\u3001\u6d41\u6dda\u548c\u75d5\u7662\u7b49\u75c7\u72c0\u3002<\/p>\n<p>\u6839\u64da\u5f17\u82e5\u65af\u7279\u6c99\u5229\u6587\u5831\u544a\uff0c\u76ee\u524d\u5168\u7403\u4e26\u7121\u6838\u51c6\u7684\u85e5\u7269\u7528\u4f86\u6cbb\u7642\u5145\u8840\u6027\u7d50\u819c\u9ec3\u6591\u3002 \u800c\u5728\u5168\u7403\u7bc4\u570d\u5167\uff0c2022\u5e74\u7d50\u819c\u9ec3\u6591\u90e8\u60a3\u8005\u4eba\u6578\u905411.496\u5104\uff0c2018\u5e74\u81f32022\u5e74\u8907\u5408\u5e74\u589e\u9577\u7387\u70ba1.2%\u3002 \u9810\u8a082027\u5e74\u5c07\u9054\u523012.171\u5104\uff0c2032\u5e74\u5c07\u9054\u523012.838\u5104\uff0c2022\u5e74\u52302027\u5e74\u8907\u5408\u5e74\u589e\u9577\u7387\u70ba1.1% \uff0c2027\u5e74\u52302032\u5e74\u8907\u5408\u589e\u9577\u7387\u70ba1.1%\u3002<\/p>\n<p>CBT-004\u662f\u4e00\u7a2e\u6f5b\u5728\u7684\u570b\u969b\u540c\u985e\u9996\u5275\u773c\u79d1\u65b0\u85e5\uff0c\u63a1\u7528\u7a81\u7834\u6027\u591a\u6fc0\u9176\u6291\u5236\u5291\uff0c\u9776\u5411\u8840\u7ba1\u5167\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4\u53ca\u8840\u5c0f\u677f\u884d\u751f\u751f\u9577\u56e0\u5b50\u53d7\u9ad4\u3002<\/p>","protected":false},"excerpt":{"rendered":"<p>We are proud to announce that CBT-004, a potential first-in-class drug for vascularised pinguecula, has completed the first patient-in for Phase 2 clinical trials in December 2023 in the US. Pinguecula is a round, yellowish, elevated tissue that develops on the conjunctiva adjacent to the cornea. Cumulative exposure to UV light is the main cause [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":736,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-744","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CBT-004 has completed the first patient-in for Phase 2 clinical trials in the US - Cloudbreak Pharma, Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cloudbreakpharma.com\/zh_hk\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\/\" \/>\n<meta property=\"og:locale\" content=\"zh_HK\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CBT-004 has completed the first patient-in for Phase 2 clinical trials in the US - Cloudbreak Pharma, Inc.\" \/>\n<meta property=\"og:description\" content=\"We are proud to announce that CBT-004, a potential first-in-class drug for vascularised pinguecula, has completed the first patient-in for Phase 2 clinical trials in December 2023 in the US. Pinguecula is a round, yellowish, elevated tissue that develops on the conjunctiva adjacent to the cornea. Cumulative exposure to UV light is the main cause [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cloudbreakpharma.com\/zh_hk\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\/\" \/>\n<meta property=\"og:site_name\" content=\"Cloudbreak Pharma, Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-05T02:05:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-22T04:39:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1363\" \/>\n\t<meta property=\"og:image:height\" content=\"575\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"James Gilbert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"James Gilbert\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9810\u8a08\u95b1\u8b80\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u5206\u9418\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\\\/\"},\"author\":{\"name\":\"James Gilbert\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/person\\\/9233f32eb4e35bf16080d902fbbd20d3\"},\"headline\":\"CBT-004 has completed the first patient-in for Phase 2 clinical trials in the US\",\"datePublished\":\"2024-03-05T02:05:12+00:00\",\"dateModified\":\"2024-03-22T04:39:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\\\/\"},\"wordCount\":198,\"publisher\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/f406cb5a7d1249474969aa8465fcf43.jpeg\",\"articleSection\":[\"News\"],\"inLanguage\":\"zh-HK\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\\\/\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\\\/\",\"name\":\"CBT-004 has completed the first patient-in for Phase 2 clinical trials in the US - Cloudbreak Pharma, Inc.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/f406cb5a7d1249474969aa8465fcf43.jpeg\",\"datePublished\":\"2024-03-05T02:05:12+00:00\",\"dateModified\":\"2024-03-22T04:39:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\\\/#breadcrumb\"},\"inLanguage\":\"zh-HK\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cloudbreakpharma.com\\\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-HK\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/f406cb5a7d1249474969aa8465fcf43.jpeg\",\"contentUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/f406cb5a7d1249474969aa8465fcf43.jpeg\",\"width\":1363,\"height\":575},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CBT-004 has completed the first patient-in for Phase 2 clinical trials in the US\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\",\"name\":\"Cloudbreak Pharma, Inc.\",\"description\":\"Seeing Life Better Through Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cloudbreakpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-HK\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#organization\",\"name\":\"Cloudbreak Pharma, Inc.\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-HK\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/cloudbreak-logo.svg\",\"contentUrl\":\"https:\\\/\\\/cloudbreakpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/cloudbreak-logo.svg\",\"width\":824,\"height\":199,\"caption\":\"Cloudbreak Pharma, Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/cloudbreakpharma.com\\\/#\\\/schema\\\/person\\\/9233f32eb4e35bf16080d902fbbd20d3\",\"name\":\"James Gilbert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-HK\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g\",\"caption\":\"James Gilbert\"},\"url\":\"https:\\\/\\\/cloudbreakpharma.com\\\/zh_hk\\\/author\\\/jgdm18gmail-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CBT-004 has completed the first patient-in for Phase 2 clinical trials in the US - Cloudbreak Pharma, Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cloudbreakpharma.com\/zh_hk\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\/","og_locale":"zh_HK","og_type":"article","og_title":"CBT-004 has completed the first patient-in for Phase 2 clinical trials in the US - Cloudbreak Pharma, Inc.","og_description":"We are proud to announce that CBT-004, a potential first-in-class drug for vascularised pinguecula, has completed the first patient-in for Phase 2 clinical trials in December 2023 in the US. Pinguecula is a round, yellowish, elevated tissue that develops on the conjunctiva adjacent to the cornea. Cumulative exposure to UV light is the main cause [&hellip;]","og_url":"https:\/\/cloudbreakpharma.com\/zh_hk\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\/","og_site_name":"Cloudbreak Pharma, Inc.","article_published_time":"2024-03-05T02:05:12+00:00","article_modified_time":"2024-03-22T04:39:22+00:00","og_image":[{"width":1363,"height":575,"url":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","type":"image\/jpeg"}],"author":"James Gilbert","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005":"James Gilbert","\u9810\u8a08\u95b1\u8b80\u6642\u9593":"2 \u5206\u9418"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cloudbreakpharma.com\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\/#article","isPartOf":{"@id":"https:\/\/cloudbreakpharma.com\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\/"},"author":{"name":"James Gilbert","@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/person\/9233f32eb4e35bf16080d902fbbd20d3"},"headline":"CBT-004 has completed the first patient-in for Phase 2 clinical trials in the US","datePublished":"2024-03-05T02:05:12+00:00","dateModified":"2024-03-22T04:39:22+00:00","mainEntityOfPage":{"@id":"https:\/\/cloudbreakpharma.com\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\/"},"wordCount":198,"publisher":{"@id":"https:\/\/cloudbreakpharma.com\/#organization"},"image":{"@id":"https:\/\/cloudbreakpharma.com\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\/#primaryimage"},"thumbnailUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","articleSection":["News"],"inLanguage":"zh-HK"},{"@type":"WebPage","@id":"https:\/\/cloudbreakpharma.com\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\/","url":"https:\/\/cloudbreakpharma.com\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\/","name":"CBT-004 has completed the first patient-in for Phase 2 clinical trials in the US - Cloudbreak Pharma, Inc.","isPartOf":{"@id":"https:\/\/cloudbreakpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cloudbreakpharma.com\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\/#primaryimage"},"image":{"@id":"https:\/\/cloudbreakpharma.com\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\/#primaryimage"},"thumbnailUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","datePublished":"2024-03-05T02:05:12+00:00","dateModified":"2024-03-22T04:39:22+00:00","breadcrumb":{"@id":"https:\/\/cloudbreakpharma.com\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\/#breadcrumb"},"inLanguage":"zh-HK","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cloudbreakpharma.com\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\/"]}]},{"@type":"ImageObject","inLanguage":"zh-HK","@id":"https:\/\/cloudbreakpharma.com\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\/#primaryimage","url":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","contentUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2023\/10\/f406cb5a7d1249474969aa8465fcf43.jpeg","width":1363,"height":575},{"@type":"BreadcrumbList","@id":"https:\/\/cloudbreakpharma.com\/cbt-004-has-completed-the-first-patient-in-for-phase-ii-clinical-trials-in-the-us\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cloudbreakpharma.com\/"},{"@type":"ListItem","position":2,"name":"CBT-004 has completed the first patient-in for Phase 2 clinical trials in the US"}]},{"@type":"WebSite","@id":"https:\/\/cloudbreakpharma.com\/#website","url":"https:\/\/cloudbreakpharma.com\/","name":"Cloudbreak Pharma, Inc.","description":"\u91ab\u85e5\u4f7f\u6211\u5011\u80fd\u66f4\u597d\u7684\u8996\u89ba\u4eab\u53d7\u751f\u6d3b","publisher":{"@id":"https:\/\/cloudbreakpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cloudbreakpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-HK"},{"@type":"Organization","@id":"https:\/\/cloudbreakpharma.com\/#organization","name":"Cloudbreak Pharma, Inc.","url":"https:\/\/cloudbreakpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-HK","@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/logo\/image\/","url":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2022\/08\/cloudbreak-logo.svg","contentUrl":"https:\/\/cloudbreakpharma.com\/wp-content\/uploads\/2022\/08\/cloudbreak-logo.svg","width":824,"height":199,"caption":"Cloudbreak Pharma, Inc."},"image":{"@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/cloudbreakpharma.com\/#\/schema\/person\/9233f32eb4e35bf16080d902fbbd20d3","name":"James Gilbert","image":{"@type":"ImageObject","inLanguage":"zh-HK","@id":"https:\/\/secure.gravatar.com\/avatar\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4b933ad216eb24252478c40c0d043d56c51e5bbebcb953a7ba6abeadbe77af31?s=96&d=mm&r=g","caption":"James Gilbert"},"url":"https:\/\/cloudbreakpharma.com\/zh_hk\/author\/jgdm18gmail-com\/"}]}},"_links":{"self":[{"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/posts\/744","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/comments?post=744"}],"version-history":[{"count":0,"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/posts\/744\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/media\/736"}],"wp:attachment":[{"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/media?parent=744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/categories?post=744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh_hk\/wp-json\/wp\/v2\/tags?post=744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}